Howland Capital Management LLC Has $16.93 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Howland Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 72.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,688 shares of the biopharmaceutical company’s stock after purchasing an additional 11,251 shares during the quarter. Howland Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $16,926,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in REGN. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after buying an additional 1,390,534 shares in the last quarter. Dodge & Cox increased its holdings in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock worth $1,653,543,000 after purchasing an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after purchasing an additional 810,144 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Regeneron Pharmaceuticals by 14.8% during the fourth quarter. Northern Trust Corp now owns 1,054,829 shares of the biopharmaceutical company’s stock valued at $751,386,000 after purchasing an additional 136,184 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Regeneron Pharmaceuticals by 30.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company’s stock valued at $699,554,000 after purchasing an additional 226,952 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.6%

REGN opened at $545.46 on Friday. The company has a fifty day moving average price of $538.64 and a two-hundred day moving average price of $604.99. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The company has a market cap of $58.89 billion, a P/E ratio of 13.89, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter in the prior year, the business earned $9.55 earnings per share. The business’s quarterly revenue was down 3.7% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is currently 8.96%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $700.00 to $580.00 in a report on Friday, May 30th. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research report on Friday, April 25th. Canaccord Genuity Group reiterated a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. The Goldman Sachs Group decreased their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. lowered their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research report on Monday, June 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $837.61.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.